232 related articles for article (PubMed ID: 29912438)
21. Oncolytic measles viruses for cancer therapy.
Nakamura T; Russell SJ
Expert Opin Biol Ther; 2004 Oct; 4(10):1685-92. PubMed ID: 15461580
[TBL] [Abstract][Full Text] [Related]
22. Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
Haralambieva I; Iankov I; Hasegawa K; Harvey M; Russell SJ; Peng KW
Mol Ther; 2007 Mar; 15(3):588-97. PubMed ID: 17245355
[TBL] [Abstract][Full Text] [Related]
23. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.
Iankov ID; Allen C; Federspiel MJ; Myers RM; Peng KW; Ingle JN; Russell SJ; Galanis E
Mol Ther; 2012 Jun; 20(6):1139-47. PubMed ID: 22334023
[TBL] [Abstract][Full Text] [Related]
24. Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain.
Wang B; Yan X; Guo Q; Li Y; Zhang H; Xie JS; Meng X
Oncotarget; 2015 Jun; 6(18):16019-30. PubMed ID: 25909216
[TBL] [Abstract][Full Text] [Related]
25. Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.
Lei J; Jacobus EJ; Taverner WK; Fisher KD; Hemmi S; West K; Slater L; Lilley F; Brown A; Champion B; Duffy MR; Seymour LW
J Immunother Cancer; 2018 Jun; 6(1):55. PubMed ID: 29898782
[TBL] [Abstract][Full Text] [Related]
26. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
27. Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment.
Sugiyama T; Yoneda M; Kuraishi T; Hattori S; Inoue Y; Sato H; Kai C
Gene Ther; 2013 Mar; 20(3):338-47. PubMed ID: 22717740
[TBL] [Abstract][Full Text] [Related]
28. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells.
Allen C; Opyrchal M; Aderca I; Schroeder MA; Sarkaria JN; Domingo E; Federspiel MJ; Galanis E
Gene Ther; 2013 Apr; 20(4):444-9. PubMed ID: 22914495
[TBL] [Abstract][Full Text] [Related]
29. Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.
Patel MR; Jacobson BA; Belgum H; Raza A; Sadiq A; Drees J; Wang H; Jay-Dixon J; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
J Thorac Oncol; 2014 Aug; 9(8):1101-10. PubMed ID: 25157763
[TBL] [Abstract][Full Text] [Related]
30. Interferon gamma protects neonatal neural stem/progenitor cells during measles virus infection of the brain.
Fantetti KN; Gray EL; Ganesan P; Kulkarni A; O'Donnell LA
J Neuroinflammation; 2016 May; 13(1):107. PubMed ID: 27178303
[TBL] [Abstract][Full Text] [Related]
31. Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice.
Lühl NC; Zirngibl F; Dorneburg C; Wei J; Dahlhaus M; Barth TF; Meyer LH; Queudeville M; Eckhoff S; Debatin KM; Beltinger C
Haematologica; 2014 Jun; 99(6):1050-61. PubMed ID: 24700491
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice.
Bernstock JD; Vicario N; Li R; Nan L; Totsch SK; Schlappi C; Gessler F; Han X; Parenti R; Beierle EA; Whitley RJ; Aban I; Gillespie GY; Markert JM; Friedman GK
Cancer Gene Ther; 2020 Apr; 27(3-4):246-255. PubMed ID: 30918335
[TBL] [Abstract][Full Text] [Related]
33. Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread.
Ayala-Breton C; Suksanpaisan L; Mader EK; Russell SJ; Peng KW
Mol Ther; 2013 Oct; 21(10):1930-7. PubMed ID: 23842448
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.
Allen C; Paraskevakou G; Iankov I; Giannini C; Schroeder M; Sarkaria J; Schroeder M; Puri RK; Russell SJ; Galanis E
Mol Ther; 2008 Sep; 16(9):1556-64. PubMed ID: 18665158
[TBL] [Abstract][Full Text] [Related]
35. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.
Achard C; Boisgerault N; Delaunay T; Roulois D; Nedellec S; Royer PJ; Pain M; Combredet C; Mesel-Lemoine M; Cellerin L; Magnan A; Tangy F; Grégoire M; Fonteneau JF
Oncotarget; 2015 Dec; 6(42):44892-904. PubMed ID: 26539644
[TBL] [Abstract][Full Text] [Related]
36. An immunocompetent murine model for oncolysis with an armed and targeted measles virus.
Ungerechts G; Springfeld C; Frenzke ME; Lampe J; Parker WB; Sorscher EJ; Cattaneo R
Mol Ther; 2007 Nov; 15(11):1991-7. PubMed ID: 17712331
[TBL] [Abstract][Full Text] [Related]
37. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Jing Y; Bejarano MT; Zaias J; Merchan JR
Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.
Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D
Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626
[TBL] [Abstract][Full Text] [Related]
39. Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.
Baldo A; Galanis E; Tangy F; Herman P
Hum Vaccin Immunother; 2016 May; 12(5):1102-16. PubMed ID: 26631840
[TBL] [Abstract][Full Text] [Related]
40. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo.
Künzi V; Oberholzer PA; Heinzerling L; Dummer R; Naim HY
J Invest Dermatol; 2006 Nov; 126(11):2525-32. PubMed ID: 16960554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
